Blockade and Reversal of Endothelin-Induced Constriction in Pial Arteries From Human Brain

Lisa N. Pierre, PhD; Anthony P. Davenport, PhD

Background and Purpose—Substantial evidence now implicates endothelin (ET) in the pathophysiology of cerebrovascular disorders such as the delayed vasospasm associated with subarachnoid hemorrhage and ischemic stroke. We investigated the ET receptor subtypes mediating vasoconstriction in human pial arteries.

Methods—ET receptors on human pial and intracerebral arteries were visualized with the use of autoradiography, and the subtypes mediating vasoconstriction were identified by means of wire myography.

Results—ET-1 was more potent than ET-3 as a vasoconstrictor, indicating an ET_A-mediated effect. Similarly, the selective ET_A agonist sarafotoxin S6c had no effect on contractile action at concentrations up to 30 nmol/L. The nonpeptide ET_A receptor antagonist PD156707 (3 to 30 nmol/L) caused a parallel rightward shift of the ET-1–induced response, yielding a pA_2 of 9.2. Consistent with these results, PD156707 (30 nmol/L) fully reversed an established constriction in pial arteries induced by 1 nmol/L ET-1, while the selective ET_B receptor antagonist BQ788 (1 μmol/L) had little effect. The calcium channel blocker nimodipine (0.3 to 3 μmol/L) significantly attenuated the maximum response to ET-1 in a concentration-dependent manner without changing potency. In agreement with the functional data, specific binding of [125I]PD151242 to ET_A receptors was localized to the smooth muscle layer of pial and intracerebral blood vessels. In contrast, little or no [125I]BQ3020 binding to ET_B receptors was detected.

Conclusions—These data indicate an important role for ET_A receptors in ET-1–induced constriction of human pial arteries and suggest that ET_A receptor antagonists may provide additional dilatory benefit in cerebrovascular disorders associated with raised ET levels. (Stroke. 1999;30:638-643.)

Key Words: calcium channel blockers ▪ cerebral arteries ▪ endothelins ▪ vasoconstriction

The endothelins1,2 (ET) are powerful vasoconstrictors that mediate their effects through 2 receptor subtypes, the ET_A and ET_B receptors.3,4 A potent and long-lasting constrictor action of ET has been described in both animal and human cerebral vasculature,3,9 leading to speculation that it may be involved in the genesis or maintenance of disorders such as the delayed vasospasm associated with subarachnoid hemorrhage (SAH) or ischemic damage after stroke. Studies attempting to correlate ET with cerebrovascular disease have described raised plasma ET levels after SAH and focal cerebral ischemia10,11 and in the cerebrospinal fluid after SAH.12 In addition, ET receptor antagonists have been shown to be beneficial in attenuating the ischemic damage and cerebral vasospasm in animal models of stroke and SAH, respectively.9,13,14 Although the effect of ET in human conduit cerebral vessels has been studied,5–7 limited information is available on the effects of ET in small cerebral arteries in humans. Given the therapeutic potential of ET receptor antagonists in cerebrovascular disease, it is of particular interest to determine which ET receptor subtype(s) mediate ET-induced vasoconstriction in these vessels.
cortical samples. Cortex was frozen and stored at −70°C until used for sectioning.

**Autoradiography**

Slide-mounted cryostat sections (10 μm) of human cerebral cortex from 5 patients were preincubated with buffer (50 mmol/L HEPES, 5 mmol/L MgCl₂, 0.3% bovine serum albumin, pH 7.4) for 15 minutes. Adjacent sections were then incubated for 2 hours in buffer containing either [¹²⁵I]PD151242 (0.1 nmol/L), to label ET₃ receptors, or [¹²⁵I]BQ3020 (0.3 nmol/L), to label ET₄ receptors. With the use of the law of mass action and data from saturation binding studies, the concentrations of ligands used have been calculated to label ~30% of the respective receptor populations. Nonspecific binding was determined by incubating adjacent sections with [¹²⁵I]PD151242 (0.1 nmol/L) or [¹²⁵I]BQ3020 (0.3 nmol/L) together with the corresponding unlabeled ligand (1 μmol/L). Sections were apposed to Hyperfilm βmax and analyzed with the use of computer-assisted densitometry. Film optical densities measured within vessels were converted to receptor density by interpolation from a standard curve. Sections were also apposed to Kodak NTB2 nuclear emulsion, and receptor binding was visualized under the microscope with dark field illumination. Adjacent sections were stained with hematoxylin and eosin to facilitate identification of vascular structures.

**In Vitro Pharmacology**

Rings of pial artery (1 to 2 mm in length) were threaded onto 40-μm-diameter stainless steel wires and mounted onto jaws within a wire myograph (model 500A; J.P. Trading) containing oxygenated modified Krebs’ solution (composition [mmol/L]: NaCl 90, KCl 5, MgSO₄ 7, H₂O 0.5, Na₂HPO₄ 1, NaCO₃ 45, CaCl₂ 2.25, glucose 10, glutamate 5, Na pyruvate 5, fumarate 5, EDTA 0.04), pH 7.4, maintained at 37°C. Isometric tension measurements were made by force transducers mounted on the myograph jaws. Output was displayed digitally on the myograph and on a Graphite chart recorder (Linton Instrumentation). After a 1-hour equilibrium period, the vessels were stretched radially, and the relation of wall tension to internal circumference was determined. With the use of the Laplace relationship, the internal diameter at which the transmural pressure was 100 mm Hg (ie, as it would be, when relaxed, in vivo) could be estimated. The vessels were then set to 90% of this internal diameter since under these conditions maximal contractile force is obtained.

Vessels were stimulated twice with a potassium-rich solution (95 mmol/L KCl) to assess contractile function. To test for a functional endothelium, vessels were contracted with the stable thromboxane mimetic U46619 (300 nmol/L), and on plateau of the response, bradykinin (100 to 300 nmol/L) was administered. Relaxation in response to bradykinin was taken as demonstration of the presence of a functional endothelium. Subsequently, cumulative concentration-response curves were constructed to either ET-1 (1 pmol/L to 300 nmol/L), ET-3 (1 pmol/L to 700 nmol/L), or the selective ET₃ receptor agonist sarafotoxin S6c (1 pmol/L to 700 nmol/L). Responses were expressed as a percentage of the potassium-induced contraction. One curve was constructed per preparation. For the antagonist studies, concentration-response curves to ET-1 were constructed in the absence or presence of either the nonpeptide, selective ET₃ receptor antagonist PD156707 (3 to 30 nmol/L) or the calcium channel blocker nimodipine (0.3 to 3 μmol/L). Antagonists were added 30 minutes before the construction of the concentration-response curves to ET-1.

In some experiments, pial arteries were preconstricted with the half-maximal concentration of ET-1. Once the response had reached a plateau, PD156707 (30 nmol/L), BQ788 (1 μmol/L), or vehicle was added.

**Materials**

[¹²⁵I]PD151242 and [¹²⁵I]BQ3020 (both ~2000 Ci·mmol⁻¹) were from Amersham International plc; ET-1, ET-3, and S6c were from Peptide Institute; unlabeled BQ3020 ([Ala¹¹,¹⁵]Ac-ET-1₁₋₉,₂₁) was synthesized by solid-phase ⁷-butoxycarbonyloxy chemistry.
arteries responded to ET-1, only 7 of the 12 arteries tested responded to ET-3. In responding arteries, ET-3 was less potent than ET-1 as a constrictor, with a mean EC$_{50}$ of 65 nmol/L (range, 8.3 to 480 nmol/L). In addition, when vessels did respond to ET-3, the contractions were more variable than those obtained to ET-1, with maximal responses ranging from 22% to 150% of the initial KCl response. The selective ETA receptor antagonist S6c was without effect in all but 1 artery tested (n=7) (Figure 1). In the artery that did respond, the E$_{max}$ was 20.7% of KCl.

The selective ETA receptor antagonist PD156707 (3 to 30 nmol/L) caused a parallel rightward shift of the concentration-response curves to ET-1 with no change in the maximal response. No portion of the ET-1 curve was resistant to the antagonist. PD156707 yielded a pA$_2$ of 9.16±0.11 (Figure 2). The slope of the Schild regression, 0.95±0.29, was not significantly different from unity (P>0.05; Student’s 2-tailed t test), indicating competitive antagonism.

The response induced by the EC$_{50}$ concentration of ET-1 (1 nmol/L) in pial arteries was maintained for >1 hour. PD156707 (30 nmol/L) elicited a full reversal of the established ET-1 response. In contrast, BQ788 (1 μmol/L) had little effect (Figure 3). The calcium channel blocker nifedipine (0.3 to 3 μmol/L) caused a significant, concentration-dependent decrease in the maximum response to ET-1 without any change in potency (n=4 to 6) (Table 2, Figure 4).

**Autoradiography**
Quantitative autoradiography revealed a high density of specific binding of the ETA ligand [125I]PD151242 to the smooth muscle layer of pial arteries (148±14 amol · mm$^{-2}$) on the surface of the cerebral cortex and intracerebral arteries (91±7 amol · mm$^{-2}$). In contrast, little or no specific binding of the ETA ligand [125I]BQ3020 to blood vessels was detected. This distribution was confirmed at higher resolution with the use of microautoradiography (Figure 5). [125I]BQ3020 binding to ETA receptors in neuronal tissue was observed, as expected, in the gray matter (70±5 amol · mm$^{-2}$) of the cortical sections.

**Discussion**
Increasing evidence supports a role for ET in the pathogenesis of cerebrovascular disease. Raised ET levels have been reported in both the plasma and cerebrospinal fluid of patients after SAH, in experimental models of these conditions, and in patients after ischemic stroke, and in experimental models of these conditions. ET receptor antagonists prevent and reverse cerebral vasospasm in animal models of SAH.

We have shown that ET is a potent constrictor of human pial arteries with long-lasting effects. The values reported here (mean EC$_{50}$, 1.2 nmol/L) are similar to those described for human large cerebral arteries and in keeping with those determined in other human small vessels such as coronary and pulmonary arteries. After SAH, angiographic evidence clearly demonstrates constriction of conducting arteries such as the middle cerebral or basilar arteries. However, little is known about their smaller branches, the pial arteries, since these are below the level of detection when angiography or transcranial Doppler sonography is used, and they are difficult to monitor. Raised local ET levels may elicit constriction in both large arteries and small cerebral arteries. In support of this hypothesis, ET applied topically to animal pial arteries, in situ, mediates a potent and sustained constriction response. A recent study demonstrated the involvement of endogenous ET in the constriction of cortical pial arterioles in the preischemic area (penumbra) after middle cerebral artery occlusion in the cat. Importantly, PD156707 was effective in restoring cerebral perfusion to ischemic penumbra after intravenous administration in this animal model.
The exact origin of the increased ET production is unclear. However, substances associated with the subarachnoid clot, such as oxyhemoglobin, thrombin, and transforming growth factor-β, have been shown to induce ET-1 production in cultured vascular endothelial and smooth muscle cells. Both animal and human cerebral endothelial cells are known to secrete ET-1, and overexpression of ET-1 by the cerebral vasculature after SAH has been suggested. The hypoxia that follows both hemorrhagic and ischemic stroke may also trigger ET production. Moreover, while the blood vessel itself maybe a source of ET, the peptide may also be produced by neuronal and glial cells, indicating a multitude of potential cellular sources within the brain.

Given the potential for beneficial dilatation of pial arteries with ET receptor antagonists, we investigated the ET receptor subtype(s) mediating ET-induced constriction in human small pial arteries. ET-1 was more potent than ET-3 as a constrictor, suggesting an ETA-mediated effect. This was supported by the lack of effect of the selective ETB receptor agonist S6c. Furthermore, the nonpeptide, selective ETA receptor antagonist PD156707 caused a parallel rightward shift of the concentration-response curves to ET-1 without a change in the maximum response, suggesting competitive antagonism of the response. Interestingly, PD156707 was a more potent antagonist in pial artery, yielding a pA2 of 9.2 compared with values of 7.5 to 8.7 in rabbit femoral artery and human peripheral blood vessels. Thus, PD156707 may allow for selective targeting of cerebral arteries and minimization of unwanted peripheral vasodilatation.

ETA receptors were localized to the intracerebral arteries and arterioles when autoradiography was used, whereas little or no ETB binding was evident. Intracerebral arterioles have been shown to be particularly sensitive to ET-1 compared with other agonists and may therefore be especially susceptible to the effects of ET. These data suggest that the ETA receptor would mediate ET-1–induced contraction in these vessels.

Under some conditions, ET receptor antagonists may need to be able to reverse an established ET-induced constriction. ET-1 (1 nmol/L)–induced contractions were maintained for 1 hour in the pial arteries. Consistent with preincubation studies, this constriction was fully reversed by PD156707 (30 nmol/L); however, BQ788 (1 μmol/L) had little effect. These experiments demonstrate that ET-1–induced constriction can be effectively reversed in these arteries.

Cerebral vessels appear to be particularly dependent on extracellular calcium for the mediation of constriction in response to various stimuli. The current drug therapy for delayed cerebral vasospasm, nimodipine, has been shown to have some selectivity for calcium channels in cerebral rather than in peripheral vessels. Although the mediators of delayed cerebral vasospasm have yet to be fully elucidated, it

<table>
<thead>
<tr>
<th>Nimodipine, μmol/L</th>
<th>ET-1 Control</th>
<th>ET-1 + Nimodipine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EC50, nmol/L</td>
<td>Emax, % KCl</td>
</tr>
<tr>
<td>0.3</td>
<td>1.5 (0.2–9.3)</td>
<td>102.3±8.7</td>
</tr>
<tr>
<td>1</td>
<td>1.0 (0.4–2.1)</td>
<td>85.9±8.5</td>
</tr>
<tr>
<td>3</td>
<td>1.5 (0.6–3.9)</td>
<td>87.6±10.7</td>
</tr>
</tbody>
</table>

Comparisons of EC50 and Emax values in the absence and presence of nimodipine were made with paired artery segments from the same patient. EC50 values are geometric mean with 95% CIs. Emax values are arithmetic mean±SEM.

*Not significantly different from control ET-1 (Mann-Whitney U test). †P<0.005, ‡P<0.05 compared with ET-1 control (Student’s paired t test).

Figure 4. Effect of the calcium antagonist nimodipine (0.3, 1, 3 μmol/L) on response to ET-1 in human small pial arteries. Values are arithmetic mean±SEM for 4 to 6 individuals and are expressed as a percentage of the response to KCl.

![Figure 4](http://stroke.ahajournals.org/)

Figure 5. Representative microautoradiogram shows binding (visualized by the presence of silver grains) of [125I]PD151242 (ETA, 0.1 nmol/L) to a pial artery lying within the sulcus of a section of cerebral cortex (a) and an intracerebral artery penetrating the white matter (d). Binding of [125I]BQ3020 (ETB, 0.3 nmol/L) to the pial (b) and intracerebral (e) arteries is also shown. Histological hematoxylin and eosin staining is shown (c and f). Bar=200 μm. g indicates gray matter; s, sulcus; and w, white matter. Arrows indicate locations of vessels.

![Figure 5](http://stroke.ahajournals.org/)

Table 2. Effect of Nimodipine (0.3–3 μmol/L) on Responses to ET-1

<table>
<thead>
<tr>
<th>Nimodipine, μmol/L</th>
<th>ET-1 Control</th>
<th>ET-1 + Nimodipine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EC50, nmol/L</td>
<td>Emax, % KCl</td>
</tr>
<tr>
<td>0.3</td>
<td>1.5 (0.2–9.3)</td>
<td>102.3±8.7</td>
</tr>
<tr>
<td>1</td>
<td>1.0 (0.4–2.1)</td>
<td>85.9±8.5</td>
</tr>
<tr>
<td>3</td>
<td>1.5 (0.6–3.9)</td>
<td>87.6±10.7</td>
</tr>
</tbody>
</table>
was anticipated that nimodipine would act as a physiological antagonist to reduce arterial spasm. There is increasing evidence to suggest that despite its ability to reduce the incidence of cerebral infarct and neuronal deficit, nimodipine does not reduce the spasm visualized by angiography. However, only the larger arteries are detected by angiography, and it is not clear whether nimodipine has some effect on the smaller pial arteries. Given the possible involvement of ET in cerebral vasospasm, we investigated the effect of nimodipine on responses to ET-1 in human small pial arteries. Nimodipine caused a reduction of the maximal response to ET-1 but did not affect its potency. Therefore, while nimodipine may partially attenuate the response to ET-1 in human pial arteries, ETA receptor antagonists are able to fully block the response over a given concentration range (Figure 6).

In conclusion, we have shown that human small pial artery smooth muscle expresses ETA receptors only and that these receptors mediate constrictor responses to ET. The response to ET can be effectively prevented or reversed with the use of an ETA receptor antagonist, and such compounds may provide additional therapeutic benefit in cerebrovascular disorders in humans.

Acknowledgments

This study was supported by grants from the British Heart Foundation, Issac Newton Trust, Royal Society, and Medical Research Council, UK. We thank Lynn Maskell and consultants of the Department of Neurosurgery, Addenbrooke’s Hospital, and the Neurosurgical Unit and Department of Neuropathology, Kings College Hospital, London, for their help in collecting tissue. We thank Dr J.J. Maguire for critical reading of the manuscript.

References

Endothelin-1 is a powerful endogenous vasoconstrictor substance produced by vascular endothelial cells. Although the exact role of endothelin-1 in the pathogenesis of cerebral vasospasm is still not completely understood, a number of studies demonstrated that endothelin antagonists might have beneficial effects on vasospasm in different experimental models of subarachnoid hemorrhage. Previous studies on isolated human cerebral arteries reported that endothelin-1 is a potent vasoconstrictor and that this effect is mediated by activation of endothelin-A (ET_A) receptors. The importance of ET_A receptors in mediation of endothelin-1 contractile effect has been confirmed by the study by Pierre and Davenport of isolated human pial arteries. They used nonpeptide ET_A receptor antagonist PD156707 to demonstrate that ET_A receptors play a key role in the vasoconstrictor effect of endothelin-1. Furthermore, they also provided evidence that ET_A receptor antagonist may reverse vasoconstrictor effect of endothelin-1, suggesting that this compound may reverse vasospasm if induced by endothelin-1. Interestingly, a calcium antagonist, nimodipine, caused a concentration-dependent decrease in maximal contraction induced with endothelin-1 without change in endothelin-1 potency. This finding suggests that the vasoconstrictor effect of low concentrations of endothelin-1 (10^-10–10^-9 M) may not be affected by nimodipine. If extrapolated to in vivo conditions, vasoconstriction of cerebral arteries to low concentrations of endothelin-1 would be resistant to vasodilator effects of nimodipine.

The authors also used quantitative autoradiography to demonstrate that ET_A receptors are localized in arterial smooth muscle cells. Both functional and autoradiographic data presented suggest that in human cerebral arteries ET_B receptors are expressed at a very low level. This observation is at variance with the demonstrated ability of ET_B receptor activation to produce endothelium-dependent relaxation in human cerebral arteries. However, technical limitations of quantitative autoradiography may be responsible for the absence of ET_B signal in single layer of endothelial cells. Based on in vitro experiments reported in the literature and in the present study, it is anticipated that ET_A receptor antagonists may have a beneficial effect on narrowing of cerebral arteries induced with endothelin-1.

**References**


Blockade and Reversal of Endothelin-Induced Constriction in Pial Arteries From Human Brain
Lisa N. Pierre and Anthony P. Davenport

Stroke. 1999;30:638-643
doi: 10.1161/01.STR.30.3.638
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/30/3/638

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/